Compositions and methods of manufacturing trivalent filovirus vaccines
US11433129B2 · kind B2 · utility
1Cited by
2References
7Claims
0Family size
Assignees
Inventors
Key dates
| Filing date | May 20, 2020 |
| Grant date | Sep 6, 2022 |
| Priority date | — |
| Expiry date | May 20, 2040 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Disclosed is a stable immunogenic composition capable of eliciting a robust and durable immune response, comprising at least one antigen consisting of a filovirus glycoprotein and at least one nano-emulsion adjuvant which are co-lyophilized and can be reconstituted immediately prior to use. Also disclosed is a vaccine composition comprising at least two antigens, wherein each antigen is specific to a different genus of filovirus and which also comprises at least one nano-emulsion adjuvant.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.